Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

pan-TRK inhibitor

DRUG CLASS:

pan-TRK inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

FGFR1 amplification	Breast Cancer	FGFR1 amplification	Breast Cancer	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2	TKI258 Sensitive: C2 – Inclusion Criteria TKI258 Sensitive : C2
FGF3 amplification	Breast Cancer	FGF3 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR2 amplification	Breast Cancer	FGFR2 amplification	Breast Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	FGFR1 amplification	Lung Non-Small Cell Squamous Cancer	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3	TKI258 Sensitive: C3 – Early Trials TKI258 Sensitive : C3
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3	ICP-723 Sensitive: C3 – Early Trials ICP-723 Sensitive : C3
FGFR2-CCDC6 fusion	Cholangiocarcinoma	FGFR2-CCDC6 fusion	Cholangiocarcinoma	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FGFR2 mutation	Endometrial Cancer	FGFR2 mutation	Endometrial Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FGFR1 overexpression	Bladder Cancer	FGFR1 overexpression	Bladder Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D
MPZL3 overexpression	Breast Cancer	MPZL3 overexpression	Breast Cancer	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D	TKI258 Sensitive: D – Preclinical TKI258 Sensitive : D